The Latest Breaking News from Vinay Prasad

Vinay Prasad resigns from the FDA after backlash over vaccine restrictions and gene therapy decisions. Political pressure cited in sudden departure.

In May, FDA Commissioner Marty Makary named Vinay Prasad the next director of the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER). Within three months, Prasad resigned.

Trump administration gives no details about reason for departure of Vinay Prasad, but he had critics and had taken unusual actions

The Food and Drug Administration named a longtime pharmaceutical executive to run the agency’s drug program

Amid Trump cuts and state-level backlash, experts worry that progress in messenger RNA vaccines could stall

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines

Frustration and anger mount as Trump administration contemplates new trials and restrictions for Covid vaccines

On May 27, 2025, Health and Human Services Secretary Robert F. Kennedy Jr. announced that the Centers for Disease Control and Prevention will no longer include the COVID-19 vaccine on the list of immunizations it recommends for healthy children and pregnant women.

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter

The Food and Drug Administration will no longer approve COVID-19 vaccines for healthy people under 65 without rigorous trials.